Effect of ranibizumab on diabetic retinopathy <i>via</i> the vascular endothelial growth factor/STAT3/glial fibrillary acidic protein pathway
Intravitreal ranibizumab modulates the VEGF/STAT3/GFAP pathway, suppresses cytokine expression, and promotes retinal repair, effectively delaying or preventing early DR progression.
Authors
- Qiong Zhou (ORCID: https://orcid.org/0000-0002-8240-0440)
- Jing Huang (ORCID: https://orcid.org/0000-0002-6827-1232)
- Ang Xiao (ORCID: https://orcid.org/0000-0003-2023-9345)
- Yulin Tao (ORCID: https://orcid.org/0000-0002-5426-834X)
- Wei‐Wen Hu (ORCID: https://orcid.org/0000-0002-7370-3394)
- Yizhen Wang (ORCID: https://orcid.org/0000-0002-3908-7102)
- Y.-C. Lin (ORCID: https://orcid.org/0000-0001-8127-6620)
- Jian Tan
Institutions
- Nanchang University (CN)
- First Affiliated Hospital of Jiangxi Medical College (CN)
- Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine (CN)
- First Affiliated Hospital of Nanchang University (CN)
Publication Details
- Journal
- World Journal of Diabetes
- Published
- 2025-04-24
- DOI
- https://doi.org/10.4239/wjd.v16.i5.99473
- Citations
- 1
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.71